Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies, Zyomyx, Surface Logix, GE Healthcare Bio-Sciences

Agilent Technologies has received US Patent No. 7,248,973, “Metrics for characterizing chemical arrays based on analysis of variance (ANOVA) factors.” The patent describes methods for producing a metric to characterize a chemical array. “Effects of terms impacting results of measurement of an output generated from analysis of the array or a procedure performed using the array, are quantified by performing ANOVA analysis and calculating sums of squares quantities attributable to each of the terms respectively,” the patent abstract states.

Agilent has also received US Patent No. 7,247,494, “Scanner with array anti-degradation features.” The patent describes a reader that “addresses the issue of damage or degradation to arrays within the reader by virtue of air exposure,” according to the patent abstract. The scanner uses a filter to reduce the amount of chemicals in the air inside the device that are harmful to the array, or the dye on the array.

Agilent has also received US Patent No. 7,247,337, “Method and apparatus for microarray fabrication.” The invention provides a method and apparatus for microarray fabrication. The method uses a housing with a gas-free chamber that fabricates microarrays with a lower defect rate, according to the patent abstract. The housing excludes gases such as ozone to prevent interaction with probe construction or attachment.

Zyomyx of Hayward, Calif., has received US Patent No. 7,247,469, “Non-specific binding resistant protein arrays and methods for making the same.” The patent describes arrays of protein-capture agents useful for detecting proteins that are the expression products of a cell or population of cells in an organism. The arrays “are particularly useful for various proteomics applications including assessing patterns of protein expression and modification in cells,” according to the patent abstract.

Surface Logix of Brighton, Mass., has received US Patent No. 7,244,598, “Biomolecule arrays.” The patent describes array systems for monitoring interactions between biological molecules with high throughput. The methods include first forming an array of immobilized biomolecules, then exposing the array to biomolecules in solution, detecting modification of the immobilized biomolecules, modifying the biomolecules in solution, and binding the biomolecules in solution to the immobilized biomolecules.

GE Healthcare Bio-Sciences of Piscataway, NJ, has received US Patent No. 7,244,566, “Analyte detection.” The patent covers a method of characterizing an analyte sample that includes the steps of: anchoring an analyte to a nucleic acid template; conducting a nucleic acid polymerase reaction to produce a labeled inorganic polyphosphate by-product; and analyzing the labeled polyphosphate.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.